Mechanism of Action
NAD+ serves as an electron carrier in redox reactions and as a substrate for several classes of enzymes critical to cellular health and aging biology.
Sirtuin Activation (Sirtuins 1–7)
Sirtuins are NAD+-dependent deacylases that regulate gene expression, DNA repair, mitochondrial biogenesis, and metabolic adaptation. SIRT1 deacetylates PGC-1α (promoting mitochondrial biogenesis) and p53 (modulating cell survival). SIRT3 regulates mitochondrial acetylation, improving oxidative phosphorylation efficiency. All seven sirtuin" class="wiki-gloss-link">sirtuin isoforms require NAD+ as an obligate substrate.[1]PARP Activation (DNA Repair)
Poly(ADP-ribose) polymerases (PARPs) consume NAD+ during DNA repair. PARP1 is activated by single- and double-strand DNA breaks and consumes up to 90% of cellular NAD+ during DNA damage responses. This NAD+ depletion link makes NAD+ restoration central to DNA repair capacity and genomic stability.[2]CD38 and NAD+ Degradation
CD38 is the primary NAD+-consuming enzyme that increases with age and inflammation. It degrades NAD+ into ADPR and cyclic ADPR, which function as secondary messengers for calcium signaling. Age-related CD38 upregulation is a major driver of declining NAD+ levels, independent of biosynthesis rates.[3]Mitochondrial Electron Transport Chain
As an electron carrier (NAD+/NADH cycling), NAD+ is required for Complex I of the electron transport chain. Low NAD+:NADH ratios impair mitochondrial respiration and ATP production, contributing to the energy deficits of aging.Research Overview
Aging & Longevity
Extensive EvidenceNAD+ restoration extends lifespan in multiple model organisms (yeast, worms, flies, mice). In mice, NAD+ precursor supplementation restores muscle function, improves vascular health, enhances cognitive performance, and reverses some hallmarks of aging. The causal relationship between NAD+ decline and aging biology is among the best-established findings in longevity research.[1]
Metabolic Health
Phase II/III ClinicalNAD+ precursors (NR, NMN) have demonstrated safety and bioavailability in human Phase I/II trials. Phase II data shows improved mitochondrial function, reduced inflammatory markers, and metabolic improvements in obese and aging subjects. Phase III trials for several indications are ongoing.[4]
Neurodegenerative Disease
Strong PreclinicalNAD+ depletion is a consistent finding in Alzheimer's, Parkinson's, and ALS models. Restoration of NAD+ levels via PARP inhibition or direct supplementation improves neurodegenerative phenotypes in multiple animal models. Human trials in neurodegenerative disease are ongoing.[5]
Alcohol & Addiction Recovery
Clinical UseHigh-dose IV NAD+ has been used in addiction medicine (IV NAD+ protocols at 500–1500 mg/day) for opioid and alcohol withdrawal, reportedly reducing cravings and withdrawal symptoms. Mechanisms involve restoration of depleted NAD+ from chronic alcohol-induced NAD+ consumption and normalization of dopaminergic signaling.[6]
Calculate your NAD+ dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Longevity / baseline | 50–100 mg | Daily | Subcutaneous |
| Metabolic support | 100 mg | Daily | Subcutaneous |
| Titration start (reduces flush) | 50 mg wk1 → 75 mg wk2 → 100 mg wk3+ | Daily | Subcutaneous |
| Energy / performance | 100 mg | Pre-workout | Subcutaneous |
Morning dosing is most common due to energy-stimulating effects that may interfere with sleep if dosed late. Titration from 50 mg to 100 mg over 2–3 weeks reduces the facial flushing and transient GI discomfort common with higher initial doses. Subcutaneous injection avoids the intense flushing associated with IV administration.
Research protocols only. Not medical advice.
Peptide & Supplement Interactions
Safety Profile
NAD+ has an excellent safety profile across human clinical trials. It is endogenous to all cells and has no established LD50 at research doses.
Flushing: Subcutaneous NAD+ can cause transient facial flushing, warmth, and itching (similar to niacin flush), particularly at doses above 50 mg or when dose escalation is too rapid. Titration protocol (50 → 75 → 100 mg over 3 weeks) significantly reduces this.
Transient nausea: Some subjects report mild nausea with initial doses. Usually resolves within 1–2 weeks.
No serious adverse events: Phase I/II human trials have not identified dose-limiting toxicities at subcutaneous doses up to 300 mg.
No FDA approval for injection: Oral NAD+ precursors (NR, NMN) are sold as supplements. Injectable NAD+ is not FDA-approved and is research/compounding use only.
References
- [1]Imai SI, Guarente L. "NAD+ and sirtuins in aging and disease." Trends Cell Biol. 2014;24(8):464-471.
- [2]Fang EF, et al. "Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction." Cell. 2014;157(4):882-896.
- [3]Camacho-Pereira J, et al. "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism." Cell Metab. 2016;23(6):1127-1139.
- [4]Martens CR, et al. "Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults." Nat Commun. 2018;9(1):1286.
- [5]Hou Y, et al. "NAD+ supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency." Proc Natl Acad Sci. 2018;115(8):E1876-E1885.
- [6]Braidy N, Villalva MD, van Eijk L. "Sobriety and Satiety: Is NAD+ the Answer?" Antioxidants (Basel). 2020;9(5):425.